- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07859722
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
A Randomized Pragmatic Study of CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate cancer. Brachytherapy is a type of radiation therapy in which radioactive implants, such as pellets, seeds, ribbons, wires, needles, balloons, or capsules, are placed in the body, directly into or near the tumor. The radiation is delivered through a flexible tube called a catheter or a larger device called an applicator. Treatment planning, or simulation, is a process used to plan radiation therapy so that the target area is precisely located and marked. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. An MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. The addition of MRI to CT for HDR prostate brachytherapy treatment planning may help patients have less urine leakage and less pain after treatment.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVE:
I. To compare acute changes in patient reported outcomes of urinary toxicity utilizing the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
SECONDARY OBJECTIVES:
I. To compare acute and chronic changes in patient reported outcomes of toxicity utilizing the EPIC-26 Urinary Irritative/Obstructive, Bowel, and Sexual domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
II. To compare the cumulative incidence of physician reported Common Terminology Criteria for Adverse Events (CTCAE) acute and chronic grade 2+ genitourinary (GU) or gastrointestinal (GI) toxicity for patients undergoing prostate HDR brachytherapy planned with utilization of an MRI versus no MRI.
TERTIARY/EXPLORATORY OBJECTIVE:
I. To compare treatment efficacy for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo treatment planning with a CT scan for HDR brachytherapy.
ARM B: Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.
After completion of study intervention, patients are followed up at 1, 3, 6, and 12 months.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Sagar Patel, MD
- Número de telefone: 404-778-1900
- E-mail: sagar.patel@emory.edu
Estude backup de contato
- Nome: Kamran Salari, MD
- Número de telefone: 404-686-2391
- E-mail: kamran.salari@emory.edu
Locais de estudo
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University Hospital/Winship Cancer Institute
-
Contato:
- Ardith Deshay
- Número de telefone: 404-251-0743
- E-mail: ardith.deshay.deshay@emory.edu
-
Investigador principal:
- Kamran Salari, MD
-
Atlanta, Georgia, Estados Unidos, 30308
- Recrutamento
- Emory University Hospital Midtown
-
Contato:
- Ardith Deshay
- Número de telefone: 404-251-0743
- E-mail: ardith.deshay.deshay@emory.edu
-
Investigador principal:
- Kamran Salari, MD
-
Atlanta, Georgia, Estados Unidos, 30308
- Recrutamento
- Emory Proton Therapy Center
-
Contato:
- Ardith DeShay
- Número de telefone: 404-251-0743
- E-mail: ardith.deshay.deshay@emory.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Men ≥ 18 years old
- Histopathologically confirmed prostate cancer
- No evidence of regional or distant metastases
- Plan to undergo curative-intent HDR brachytherapy with or without external beam radiation therapy
Exclusion Criteria:
- Prior pelvic radiation therapy
- No prior prostate MRI
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm A (CT, SOC HDR brachytherapy)
Patients undergo treatment planning with a CT scan for HDR brachytherapy. |
Ancillary studies |
|
Experimental: Arm B (CT, MRI, SOC HDR brachytherapy)
Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy. |
Ancillary studies Undergo MRI scan
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Prazo: At 1 month following treatment
|
The primary analysis will be conducted using a mixed-effects model for repeated measures (MMRM) including fixed effects for treatment arm, categorical time, treatment-by-time interaction, baseline Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence score, age, comorbidity status, and the stratification factors of high-dose-rate treatment approach and rectal spacer use. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. The primary treatment comparison will be the adjusted between-group difference at the 1-month time point derived from the treatment-by-time interaction using least-squares means, with corresponding two-sided 95% confidence intervals and p-values evaluated at a significance level of 0.05. |
At 1 month following treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Prazo: At 3, 6 and 12 months following treatment
|
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. |
At 3, 6 and 12 months following treatment
|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scores
Prazo: At 1, 3, 6 and 12 months following treatment
|
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary irritative/obstructive, bowel, and sexual domain scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. |
At 1, 3, 6 and 12 months following treatment
|
|
Cumulative incidence of grade 2 or higher genitourinary or gastrointestinal adverse events
Prazo: Within 12 months following treatment
|
Will be analyzed using competing-risk methods to account for death as a competing event. Cumulative incidence functions will be estimated for each treatment arm and compared using Gray's test. Fine-Gray subdistribution hazard models, including stratification factors and relevant covariates, will be used to estimate adjusted hazard ratios with 95% confidence intervals. Adverse events will be coded using the Medical Dictionary for Regulatory Activities and graded according to Common Terminology Criteria for Adverse Events version 5.0. Safety analyses will summarize the frequency, severity, and relationship of adverse events to study treatment by System Organ Class and preferred term. Each adverse event will be counted once per participant at the maximum severity grade. Serious adverse events and events leading to treatment discontinuation will be summarized separately. |
Within 12 months following treatment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kamran Salari, MD, Emory University Hospital/Winship Cancer Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Neoplasias Genitais Masculinas
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças prostáticas
- Doenças Urogenitais Masculinas
- Neoplasias prostáticas
- Técnicas de investigação
- Técnicas de química, analíticas
- Análise de espectro
- Espectroscopia de ressonância magnética
Outros números de identificação do estudo
- 2026P000571
- P30CA138292 (Concessão/Contrato do NIH dos EUA)
- NCI-2026-06309 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- 2026P000571 (Outro identificador: Emory University Hospital/Winship Cancer Institute)
- RAD6975-26 (Outro identificador: Emory University Hospital/Winship Cancer Institute)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .